New RSV shots slash baby hospitalizations? study digs into Real-World data
NCT ID NCT07164430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether new RSV prevention medicines given to infants or pregnant women reduced hospitalizations for RSV in children under 2. Researchers analyzed health records from over 2,700 children in the Australian Capital Territory. The goal was to see if the 2025 prevention program made a difference in RSV-related hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could show that RSV prevention programs reduce hospitalizations in young children, guiding future public health policies.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other regions or populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Canberra Hospital
Garran, Australian Capital Territory, 2605, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RSV shot uptake under the microscope: how many german babies get protected?
- Double defense: new mRNA vaccine targets two lung viruses in seniors
- New mRNA vaccine aims to shield seniors from RSV
- New mRNA vaccine candidates for RSV enter human testing
- RSV prevention drug shows promise in first year of use